top of page
  • CombatThePatentPrices

The War on Warfarin

The Coumadin(Warfarin) court case emerged out of charges that DuPont Merck Pharmaceutical Company, later known as DuPont Pharmaceuticals Company ("DuPont"), with an unlawful plan to increase deals and benefits of its warfarin sodium product, a blood thinning drug with the brand name of Coumadin. It did as such by puting unneeded and unjustified concern on less expensive general versions of it.

DuPont has had an imposing monopoly l in the market for warfarin for quite a long time, notwithstanding the way that its patent for the medication terminated in 1962. In 1997, Barr Laboratories, Inc. acquired FDA endorsement for a conventional equal to Coumadin. In negligence of the FDA's assurance that Barr's conventional item was similarly as sheltered and powerful as its image name, DuPont reacted with false marketing and unwarranted news and fake alerts to paint an image of fear in its less expensive competition.

Offended parties were purchasers and outsider payers who claimed that DuPont had scattered misinformation and explanations about the safety and effect of a competitors general cheaper substitute item, with that outcome that people were just paying more for DuPont's image name item. They arranged a $44.5 million settlement.

1.8 million customers of a physician endorsed drug promoted by DuPont Merck Pharmaceuticals under the brand name Coumadin. Utilized as a blood thinning drug, Coumadin is one of the most endorsed meds in the United States has now been dealt a blow of 44.5 million because of how they unlawfully and falsely kept up a large portion of its unique restrictive control of the market of Warfarin by spreading misleading data to patients, specialists, and drug specialists about the quality and adequacy of Coumadin's partner, the FDA-endorsed conventional medication, warfarin sodium.

By: Vivee Karthikeyan

20 views0 comments

Recent Posts

See All


bottom of page